Vaccine Technologies Market Synopsis

Vaccine Technologies Market Size Was Valued at USD 45.6 Billion in 2023, and is Projected to Reach USD 112 Billion by 2032, Growing at a CAGR of 10.5% From 2024-2032.

The Vaccine Technologies Market means the field that involves the discovery, creation, synthesis, production, and supply of vaccines, which are biological products intended to protect individuals against specific diseases. These vaccines help the body in that they get the immune system to identify infecting agents such as the virus or bacteria. It also includes variety of technologies used in the live-attenuated vaccines, inactivated vaccines, subunit and recombinant vaccines, mRNA vaccines and viral vector vaccines.

• Globally, the size of the vaccine technologies market has been on the rise for the past decade given the increasing cases of infectious diseases as well as growing focus on preventive health. This is informs of one or other government campaign, which increases vaccination rates among people in the world. Furthermore, the improving market for biotechnology and the next-generation vaccines, including the mRNA-based or DNA vaccines have opened a new horizons for it. The COVID-19 also highlighted the development and distribution of vaccines in line with several principles on a never before seen scale which makes wart technologies all the more crucial.
• In addition, major stakeholders are allocating large amounts of resources to discovering new vaccines for newly detected diseases, systematic diseases, cancer, and other systemic illnesses, as well as genospecific immunization. Partnerships have also accelerated fast in the current decade between pharmaceutical firms, as well as the biotechnology companies have also pushed the accelerated development of vaccines. For this reason, the market is expected to expand during the entirety of the forecast period due to greater demand for vaccines, enhanced manufacturing processes, and government support.

Vaccine Technologies Market Trend Analysis

Growth in mRNA Vaccine Technologies

• One of the key emerging opportunities in the vaccine technologies market is the increased uptake of mRNA vaccines in particular after the COVID-19 successes of these novel vaccines which work by teaching cells to produce a protein to elicit an immune response to diseases. The technology brings some benefits for the production including the higher velocity, easy to scale up, and suitability for the different diseases. Using the recent examples of COVID-19 vaccines developed by Pfizer and Moderna, mRNA vaccine technology is being considered for other virus diseases including influenza and HIV and for cancer vaccines. This what has shaped what is now seen as indications that mRNA vaccines could offer new approaches in addressing many of the challenges facing the vaccine market.

Expansion into Emerging Markets

• The major potential in the Distributed Network of Vaccine Technologies is in extending the availability of vaccines in the developing world, particularly Africa, Asia, and Latin America. These regions having relatively low vaccine uptake have often been associated with economic, practical and health system constraints such as inadequate storage of vaccines and poors access to vaccines. But heightened awareness for immunization around the world and the efforts put in by WHO, Gavi and many other not-for-profits have thrown the door wide open for much more market opportunities. With governments and international organisations strengthening efforts to extend access to health and upgrade the physical structures put in place to facilitate such access, vaccine producers get an opportunity to increase market coverage in these areas. When implemented properly to address the issues of cost and outreach, firms have a great chance to widen access to protective vaccines and use demand for superior vaccine forms.

Vaccine Technologies Market Segment Analysis:

Vaccine Technologies Market Segmented on the basis of Technology, Route Of Administration and Age Group.

By Technology, Live-attenuated vaccines segment is expected to dominate the market during the forecast period

• Consequently, within the geographical landscape, the live-attenuated vaccines segment is anticipated to be the leading growth provider for the vaccine technologies in the given timeframe. Live-attenuated vaccines are vaccines which contain a form of the living microbe that cannot harm healthy individuals through causing illness. It has been utilized for more than one generation of children for vaccines of measles, mumps, rubella, and chickenpox. Live-attenuated vaccines are very effective since the immune response they elicit is usually mighty and enduring; generally, the antibodies need less booster shots. 202 live delayed vaccines are still popular in immunization programs, including countries with more developed vaccines, such as live-attenuated vaccines. The effectiveness of such vaccines and the versatility of the application make this segment one of the greatest shares of the overall vaccine market.

By Route Of Administration, Parenteral segment expected to held the largest share

• In terms of route of administration, parenteral is further expected to dominate the vaccine technologies market share. Injectable as it means the administration of vaccines through injections either intramuscular, intravenous or subcutaneous. This route is considered to be effective since it allows for penetration to the bloodstream; it produces quick and powerful immune response. The majority of the vaccines that exist in today’s world such as COVID-19, seasonal flu, hepatitis, and polio vaccines are invasive. Shot induced vaccines forms a large chunk of the vaccines in use due to their effectiveness and ease in large scale production. With the advent of new vaccines and especially due to pandemics the parenteral route of delivery will remain the most preferred which will give further boost to this segment of the global market.

Vaccine Technologies Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• Market analysis indicates that by the year 2023 North America will account for the largest market share in vaccine technologies. The level of leadership of the region can be explained by the availability of operational health care systems, extensive funding on research, and government drive towards encouraging immunization. The US alone ranks high in demand for vaccines, and many vaccine manufacturing firms are based in this nation. It is predicted that over 40% of North America will seize the global market due to its technology advancement and an increasing number of measures implemented to fight against diseases. The very high level of public awareness in the region, increased healthcare funding, and early involvement in vaccine R&D all lead to keeping the region at the forefront of the global vaccine technologies market.

Active Key Players in the Vaccine Technologies Market

• AstraZeneca (UK)
• Bharat Biotech (India)
• BioNTech (Germany)
• CSL Limited (Australia)
• CureVac (Germany)
• GlaxoSmithKline (UK)
• Johnson & Johnson (USA)
• Merck & Co. (USA)
• Moderna (USA)
• Novavax (USA)
• Pfizer (USA)
• Sanofi (France)
• Serum Institute of India (India)
• Sinovac (China)
• Takeda Pharmaceutical (Japan)
• Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Vaccine Technologies Market by Technology
 4.1 Vaccine Technologies Market Snapshot and Growth Engine
 4.2 Vaccine Technologies Market Overview
 4.3 Live-attenuated vaccines
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Live-attenuated vaccines: Geographic Segmentation Analysis
 4.4 Inactivated vaccines
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Inactivated vaccines: Geographic Segmentation Analysis
 4.5 Subunit vaccines
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Subunit vaccines: Geographic Segmentation Analysis
 4.6 Toxoid vaccines
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Toxoid vaccines: Geographic Segmentation Analysis
 4.7 Viral vector vaccines
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Viral vector vaccines: Geographic Segmentation Analysis
 4.8 Messenger RNA (mRNA) vaccines
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Messenger RNA (mRNA) vaccines: Geographic Segmentation Analysis

Chapter 5: Vaccine Technologies Market by Route Of Administration
 5.1 Vaccine Technologies Market Snapshot and Growth Engine
 5.2 Vaccine Technologies Market Overview
 5.3 Parenteral
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Parenteral: Geographic Segmentation Analysis
 5.4 Oral
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Oral: Geographic Segmentation Analysis
 5.5 Nasal
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Nasal: Geographic Segmentation Analysis

Chapter 6: Vaccine Technologies Market by Age Group
 6.1 Vaccine Technologies Market Snapshot and Growth Engine
 6.2 Vaccine Technologies Market Overview
 6.3 Pediatric
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Pediatric: Geographic Segmentation Analysis
 6.4 Adult
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Adult: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Vaccine Technologies Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ASTRAZENECA (UK)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 BHARAT BIOTECH (INDIA)
 7.4 BIONTECH (GERMANY)
 7.5 CSL LIMITED (AUSTRALIA)
 7.6 CUREVAC (GERMANY)
 7.7 GLAXOSMITHKLINE (UK)
 7.8 JOHNSON & JOHNSON (USA)
 7.9 MERCK & CO (USA)
 7.10 MODERNA (USA)
 7.11 NOVAVAX (USA)
 7.12 PFIZER (USA)
 7.13 SANOFI (FRANCE)
 7.14 SERUM INSTITUTE OF INDIA (INDIA)
 7.15 SINOVAC (CHINA)
 7.16 TAKEDA PHARMACEUTICAL (JAPAN)
 7.17 OTHER KEY PLAYERS

Chapter 8: Global Vaccine Technologies Market By Region
 8.1 Overview
 8.2. North America Vaccine Technologies Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Technology
  8.2.4.1 Live-attenuated vaccines
  8.2.4.2 Inactivated vaccines
  8.2.4.3 Subunit vaccines
  8.2.4.4 Toxoid vaccines
  8.2.4.5 Viral vector vaccines
  8.2.4.6 Messenger RNA (mRNA) vaccines
  8.2.5 Historic and Forecasted Market Size By Route Of Administration
  8.2.5.1 Parenteral
  8.2.5.2 Oral
  8.2.5.3 Nasal
  8.2.6 Historic and Forecasted Market Size By Age Group
  8.2.6.1 Pediatric
  8.2.6.2 Adult
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Vaccine Technologies Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Technology
  8.3.4.1 Live-attenuated vaccines
  8.3.4.2 Inactivated vaccines
  8.3.4.3 Subunit vaccines
  8.3.4.4 Toxoid vaccines
  8.3.4.5 Viral vector vaccines
  8.3.4.6 Messenger RNA (mRNA) vaccines
  8.3.5 Historic and Forecasted Market Size By Route Of Administration
  8.3.5.1 Parenteral
  8.3.5.2 Oral
  8.3.5.3 Nasal
  8.3.6 Historic and Forecasted Market Size By Age Group
  8.3.6.1 Pediatric
  8.3.6.2 Adult
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Vaccine Technologies Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Technology
  8.4.4.1 Live-attenuated vaccines
  8.4.4.2 Inactivated vaccines
  8.4.4.3 Subunit vaccines
  8.4.4.4 Toxoid vaccines
  8.4.4.5 Viral vector vaccines
  8.4.4.6 Messenger RNA (mRNA) vaccines
  8.4.5 Historic and Forecasted Market Size By Route Of Administration
  8.4.5.1 Parenteral
  8.4.5.2 Oral
  8.4.5.3 Nasal
  8.4.6 Historic and Forecasted Market Size By Age Group
  8.4.6.1 Pediatric
  8.4.6.2 Adult
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Vaccine Technologies Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Technology
  8.5.4.1 Live-attenuated vaccines
  8.5.4.2 Inactivated vaccines
  8.5.4.3 Subunit vaccines
  8.5.4.4 Toxoid vaccines
  8.5.4.5 Viral vector vaccines
  8.5.4.6 Messenger RNA (mRNA) vaccines
  8.5.5 Historic and Forecasted Market Size By Route Of Administration
  8.5.5.1 Parenteral
  8.5.5.2 Oral
  8.5.5.3 Nasal
  8.5.6 Historic and Forecasted Market Size By Age Group
  8.5.6.1 Pediatric
  8.5.6.2 Adult
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Vaccine Technologies Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Technology
  8.6.4.1 Live-attenuated vaccines
  8.6.4.2 Inactivated vaccines
  8.6.4.3 Subunit vaccines
  8.6.4.4 Toxoid vaccines
  8.6.4.5 Viral vector vaccines
  8.6.4.6 Messenger RNA (mRNA) vaccines
  8.6.5 Historic and Forecasted Market Size By Route Of Administration
  8.6.5.1 Parenteral
  8.6.5.2 Oral
  8.6.5.3 Nasal
  8.6.6 Historic and Forecasted Market Size By Age Group
  8.6.6.1 Pediatric
  8.6.6.2 Adult
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Vaccine Technologies Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Technology
  8.7.4.1 Live-attenuated vaccines
  8.7.4.2 Inactivated vaccines
  8.7.4.3 Subunit vaccines
  8.7.4.4 Toxoid vaccines
  8.7.4.5 Viral vector vaccines
  8.7.4.6 Messenger RNA (mRNA) vaccines
  8.7.5 Historic and Forecasted Market Size By Route Of Administration
  8.7.5.1 Parenteral
  8.7.5.2 Oral
  8.7.5.3 Nasal
  8.7.6 Historic and Forecasted Market Size By Age Group
  8.7.6.1 Pediatric
  8.7.6.2 Adult
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research